Jihua Chen (Regeneron, NY, USA) author of ‘Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH’ published in Bioanalysis gives us an insight into his research and some of the major challenges in the field.
Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH
It is documented that soluble drug targets in clinical study samples have generated false positive results in anti-drug antibody bridging assays due to target-mediated bridging. In this research paper read about strategies to mitigate target interference.
In this research article from Bioanalysis learn more about the immunogenicity of anti-body drug conjugates. The research follows eight molecules across 11 clinical trials to evaluate the potentially increased immunogenicity risk of these multi-domain biotherapeutics compared with monoclonal antibodies.
Author Montserrat Carrasco-Triguero (Genentech, CA, USA) gives us an insight into her research career and her paper published in Bioanalysis: Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials, in this author’s perspective feature.
In this report you can find a summary of the presentations from the analytical and bioanalytical day of the 2019 World ADC Summit, held in San Diego (CA, USA) which was attended by approximately 60 scientists from industry and academia.
In this feature, we explore the key qualities to look for to ensure success when outsourcing immunogenicity assay development and testing. We also explore the methods for – and challenges involved with – T-cell immunity monitoring and assay development.
This infographic highlights the key qualities to look for in a CRO to ensure the best results when outsourcing immunogenicity assay development and testing.
In this interview Joel Mathews (Ionis Pharmaceuticals Inc., CA, USA) discusses his role in the development of biomarker, PK and immunogenicity assays in the development of protein therapeutics. He explains his interest in the field and explores the use of LBA for biomarker validation
In this article from Bioanalysis, the authors give their perspectives and findings in exploring a hybrid LBA/LC–MS as an orthogonal bioanalytical tool for clinical immunogenicity assessments.
In this editorial Sally Fischer (Genentech; CA, USA) explores ligand binding assay technologies: how to match the right tool to the bioanalytical challenge.